Alnylam Pharmaceuticals (ALNY) FCF Margin (2009 - 2026)
Alnylam Pharmaceuticals posted quarterly FCF Margin of 4.17% for Q1 2026, up 43511.0% year-on-year from N/an in Q1 2025, and down 67.39% on a QoQ basis from 12.79% in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 18 years of FCF Margin data on file, last reported at 4.17% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 43511.0% year-over-year to 4.17%; the trailing twelve-month figure through Mar 2026 stood at 15.01% (up 1995.0% YoY), and the FY2025 full-year result was 12.53%, up 1443.0% from the prior year.
- FCF Margin for Q1 2026 stood at 4.17%, down from 12.79% in the prior quarter.
- Across five years, FCF Margin topped out at 45.61% in Q3 2023 and bottomed at 430.94% in Q1 2025.
- The 5-year median for FCF Margin is 16.94% (2024), against an average of 38.34%.
- The widest annual swing landed in 2025, when FCF Margin sank 41400 bps; it then surged 43511 bps in 2026.
- A 5-year view of FCF Margin shows it stood at 25.9% in 2022, then surged by 60 bps to 10.26% in 2023, then plunged by 71 bps to 17.49% in 2024, then surged by 173 bps to 12.79% in 2025, then slumped by 67 bps to 4.17% in 2026.
- The last three FCF Margin figures came in at 4.17% (Q1 2026), 12.79% (Q4 2025), and 23.52% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.17% |
| Dec 31, 2025 | 12.79% |
| Sep 30, 2025 | 23.52% |
| Jun 30, 2025 | 20.76% |
| Mar 31, 2025 | -430.94% |
| Dec 31, 2024 | -17.49% |
| Sep 30, 2024 | 3.91% |
| Jun 30, 2024 | 19.00% |
| Mar 31, 2024 | -16.94% |
| Dec 31, 2023 | -10.26% |
| Sep 30, 2023 | 45.61% |
| Jun 30, 2023 | -23.50% |
| Mar 31, 2023 | -56.49% |
| Dec 31, 2022 | -25.90% |
| Sep 30, 2022 | -49.86% |
| Jun 30, 2022 | -66.02% |
| Mar 31, 2022 | -84.18% |
| Dec 31, 2021 | -42.26% |
| Sep 30, 2021 | -85.33% |
| Jun 30, 2021 | -64.83% |
| Mar 31, 2021 | -136.82% |
| Dec 31, 2020 | -88.54% |
| Sep 30, 2020 | -97.53% |
| Jun 30, 2020 | -146.20% |
| Mar 31, 2020 | -267.18% |
| Dec 31, 2019 | -152.77% |
| Sep 30, 2019 | -312.14% |
| Jun 30, 2019 | 528.77% |
| Mar 31, 2019 | -605.34% |
| Dec 31, 2018 | -1,224.77% |
| Sep 30, 2018 | -6,263.03% |
| Jun 30, 2018 | -419.28% |
| Mar 31, 2018 | -807.90% |
| Dec 31, 2017 | -326.37% |
| Sep 30, 2017 | -725.56% |
| Jun 30, 2017 | -644.61% |
| Mar 31, 2017 | -719.84% |
| Dec 31, 2016 | -382.79% |
| Sep 30, 2016 | -702.03% |
| Jun 30, 2016 | -982.06% |
| Mar 31, 2016 | -1,261.81% |
| Dec 31, 2015 | -743.78% |
| Sep 30, 2015 | -962.08% |
| Jun 30, 2015 | -653.08% |
| Mar 31, 2015 | -153.02% |
| Dec 31, 2014 | -167.21% |
| Sep 30, 2014 | -400.12% |
| Jun 30, 2014 | -664.52% |
| Mar 31, 2014 | -508.31% |
| Dec 31, 2013 | -178.87% |
| Sep 30, 2013 | -252.09% |
| Jun 30, 2013 | -276.06% |
| Mar 31, 2013 | -14.86% |
| Dec 31, 2012 | -737.98% |
| Sep 30, 2012 | -3.08% |
| Jun 30, 2012 | -111.88% |
| Mar 31, 2012 | -148.04% |
| Dec 31, 2011 | -125.56% |
| Sep 30, 2011 | -140.88% |
| Jun 30, 2011 | -131.24% |
| Mar 31, 2011 | -30.31% |
| Dec 31, 2010 | -101.58% |
| Sep 30, 2010 | -90.74% |
| Jun 30, 2010 | -96.72% |
| Mar 31, 2010 | -67.98% |
| Dec 31, 2009 | -68.11% |
| Sep 30, 2009 | -87.94% |